PORTAGE, Mich., March 4, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its Steri-Shield 8 personal protection system, the latest in its personal protective equipment (PPE). Steri-Shield 8 was designed through years of research, testing and collaboration with real-world users.
"Over the last 30 years, we have relentlessly innovated our personal protection system to address the needs of today's professionals and prioritize the safety and well-being of care team members and patients," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business. "As the personal protection system leader in the market, we're pleased to introduce the Steri-Shield 8 system to further enhance protection and wearability."
The Steri-Shield 8 personal protection system includes a helmet with three points of contact for a customizable fit, a sleeker battery, a more efficient charging station and three toga styles.
Key features include:
For more information, visit: https://www.stryker.com/us/en/orthopaedic-instruments/products/steri-shield-8.html
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
*Stryker internal data
Media Contact:
Beth Sizemore
Sr. Director, Strategic Communications, Instruments
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$373.92 |
Daily Change: | 3.00 0.81 |
Daily Volume: | 2,159,145 |
Market Cap: | US$142.550B |
March 03, 2025 January 28, 2025 January 28, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load